CY1107262T1 - Θεραπεια της εξαρτησης στερησης - Google Patents
Θεραπεια της εξαρτησης στερησηςInfo
- Publication number
- CY1107262T1 CY1107262T1 CY20081100020T CY081100020T CY1107262T1 CY 1107262 T1 CY1107262 T1 CY 1107262T1 CY 20081100020 T CY20081100020 T CY 20081100020T CY 081100020 T CY081100020 T CY 081100020T CY 1107262 T1 CY1107262 T1 CY 1107262T1
- Authority
- CY
- Cyprus
- Prior art keywords
- buprenorphine
- dosage form
- dosage
- days
- dosing period
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 7
- 229960001736 buprenorphine Drugs 0.000 abstract 7
- 239000002552 dosage form Substances 0.000 abstract 4
- 239000006211 transdermal dosage form Substances 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B2101/00—Type of solid waste
- B09B2101/65—Medical waste
- B09B2101/68—Transdermal patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Drying Of Semiconductors (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Περιγράφονται φαρμακευτικές αγωγές δοσολόγησης μπουπρενορφίνης για να θεραπεύεται σύνδρομο στέρησης ή αποχής, σε μια ασθενή που είναι έγκυος που έχει εξάρτηση φαρμάκου ή είναι ανεκτικός σε οπιοειδές. Η μέθοδος περιλαμβάνει θεραπεία συνδρόμου στέρησης ή αποχής του ασθενούς με διαδερματική χορήγηση μιας ποσότητος μπουπρενορφίνης αποτελεσματικής για να μειώνονται τα συμπτώματα στέρησης. Για παράδειγμα, μία πρώτη διαδερματική μορφή δοσολογίας που περιέχει μπουπρενορφίνη μπορεί να χορηγηθεί για μία πρώτη περίοδο δοσολόγησης που είναι όχι μεγαλύτερη από περίπου 5 ημέρες, μία δεύτερη περιέχουσα μπουπρενορφίνη διαδερματική μορφή δοσολογίας για μία δεύτερη περίοδο δοσολόγησης, η οποία είναι όχι μεγαλύτερη από περίπου 5 ημέρες, η δεύτερη δε μορφή δοσολογίας περιλαμβάνει την ίδια ή μεγαλύτερη δοσολογία μπουπρενορφίνης από ότι η πρώτη μορφή δοσολογίας και μία τρίτη περιέχουσα μπουπρενορφίνη διαδερματική μορφή δοσολογίας για μία δεύτερη περίοδο δοσολόγησης, που είναι τουλάχιστον 2 ημέρες, η δε τρίτη μορφή δοσολογίας περιλαμβάνει την ίδια ή μεγαλύτερη δοσολογία μπουπρενορφίνης από ότι η δεύτερη μορφή δοσολογίας.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49040703P | 2003-07-25 | 2003-07-25 | |
| EP04779186A EP1646328B1 (en) | 2003-07-25 | 2004-07-26 | Treatment of dependence withdrawal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107262T1 true CY1107262T1 (el) | 2012-11-21 |
Family
ID=34115390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100020T CY1107262T1 (el) | 2003-07-25 | 2008-01-08 | Θεραπεια της εξαρτησης στερησης |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8637073B2 (el) |
| EP (1) | EP1646328B1 (el) |
| JP (2) | JP2007500134A (el) |
| KR (1) | KR100829492B1 (el) |
| CN (1) | CN1829482B (el) |
| AT (1) | ATE375149T1 (el) |
| AU (1) | AU2004261182B2 (el) |
| BR (1) | BRPI0412931A (el) |
| CA (1) | CA2530005C (el) |
| CY (1) | CY1107262T1 (el) |
| DE (1) | DE602004009449T2 (el) |
| DK (1) | DK1646328T3 (el) |
| EA (1) | EA009921B1 (el) |
| ES (1) | ES2295929T3 (el) |
| GE (1) | GEP20125454B (el) |
| HR (1) | HRP20070476T3 (el) |
| IL (1) | IL173346A (el) |
| IS (1) | IS2630B (el) |
| MA (1) | MA28004A1 (el) |
| MX (1) | MXPA06000991A (el) |
| NO (1) | NO333189B1 (el) |
| NZ (1) | NZ545505A (el) |
| PL (1) | PL1646328T3 (el) |
| PT (1) | PT1646328E (el) |
| SI (1) | SI1646328T1 (el) |
| UA (1) | UA81056C2 (el) |
| WO (1) | WO2005011579A2 (el) |
| ZA (1) | ZA200510069B (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| EP1913938A1 (en) * | 2002-12-13 | 2008-04-23 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
| MXPA05006334A (es) * | 2002-12-13 | 2005-08-26 | Euro Celtique Sa | Dosis de buprenorfina transdermica para analgesia. |
| WO2005011579A2 (en) | 2003-07-25 | 2005-02-10 | Euro-Celtique S.A. | Treatment of dependence withdrawal |
| EP1931421A1 (en) * | 2005-09-30 | 2008-06-18 | Tti Ellebeau, Inc. | Transdermal drug delivery systems, devices, and methods employing opioid agonist and/or opioid antagonist |
| JP2011513287A (ja) * | 2008-02-28 | 2011-04-28 | シントロファーマ リミテッド | 医薬品組成物 |
| US8163731B2 (en) * | 2008-08-20 | 2012-04-24 | Rhodes Technologies | Method and dosage regimens for eliminating a chemical substance in blood |
| WO2011116243A1 (en) | 2010-03-17 | 2011-09-22 | Method Products, Inc. | Liquid cleaning compositions with lower freezing point |
| US11236351B2 (en) | 2010-05-17 | 2022-02-01 | Dow Agrosciences Llc | Production of DHA and other LC PUFAs in plants |
| TW201307553A (zh) | 2011-07-26 | 2013-02-16 | Dow Agrosciences Llc | 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術 |
| WO2013156850A1 (en) | 2012-04-17 | 2013-10-24 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| DK3400066T3 (da) * | 2016-01-08 | 2021-10-18 | Ohio State Innovation Foundation | Behandlinger og forebyggelse af neonatalt opioidt abstinenssyndrom |
| CN107648234A (zh) * | 2017-08-04 | 2018-02-02 | 中国人民解放军第二军医大学 | 一种治疗***成瘾戒断症状的阿片类药物组合物 |
| WO2019199704A1 (en) * | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Oxytocin compositions and methods of use |
| US20220288061A1 (en) * | 2019-09-02 | 2022-09-15 | Camurus Ab | Formulations and treatment methods |
| EP4284506A1 (en) * | 2021-02-01 | 2023-12-06 | Clear Scientific, Inc. | Sequestration compounds for treatment of substance use disorder and uses thereof |
| WO2024036337A2 (en) * | 2022-08-12 | 2024-02-15 | Bio Ventures, Llc | Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4058599A (en) | 1973-02-24 | 1977-11-15 | Bayer Aktiengesellschaft | Ethyleneimine inactivated organisms |
| DE3939376C1 (el) * | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for ***e abuse |
| EP0432945A1 (en) * | 1989-12-12 | 1991-06-19 | Warner-Lambert Company | A transdermal delivery system for treatment of ***e and heroin addiction |
| US5272149A (en) * | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
| JPH06183956A (ja) | 1992-12-24 | 1994-07-05 | Teisan Seiyaku Kk | 安定な貼付用の製剤 |
| JP2819236B2 (ja) | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
| EP0821957A3 (en) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| KR100383252B1 (ko) | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
| US20030114475A1 (en) * | 2001-10-31 | 2003-06-19 | Addiction Therapies, Inc. | Methods for the treatment of addiction |
| ES2305457T3 (es) | 2002-03-20 | 2008-11-01 | Euro-Celtique S.A. | Metodo de administracion de buprenorfina para tratar la depresion. |
| MXPA05006334A (es) | 2002-12-13 | 2005-08-26 | Euro Celtique Sa | Dosis de buprenorfina transdermica para analgesia. |
| WO2004103317A2 (en) | 2003-05-15 | 2004-12-02 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for treatment of diarrhea |
| WO2005011579A2 (en) | 2003-07-25 | 2005-02-10 | Euro-Celtique S.A. | Treatment of dependence withdrawal |
-
2004
- 2004-07-26 WO PCT/US2004/024010 patent/WO2005011579A2/en active IP Right Grant
- 2004-07-26 EP EP04779186A patent/EP1646328B1/en active Active
- 2004-07-26 US US10/566,121 patent/US8637073B2/en active Active
- 2004-07-26 PL PL04779186T patent/PL1646328T3/pl unknown
- 2004-07-26 DK DK04779186T patent/DK1646328T3/da active
- 2004-07-26 SI SI200430545T patent/SI1646328T1/sl unknown
- 2004-07-26 AU AU2004261182A patent/AU2004261182B2/en not_active Ceased
- 2004-07-26 JP JP2006521307A patent/JP2007500134A/ja active Pending
- 2004-07-26 DE DE602004009449T patent/DE602004009449T2/de active Active
- 2004-07-26 ES ES04779186T patent/ES2295929T3/es active Active
- 2004-07-26 BR BRPI0412931-8A patent/BRPI0412931A/pt not_active Application Discontinuation
- 2004-07-26 MX MXPA06000991A patent/MXPA06000991A/es active IP Right Grant
- 2004-07-26 GE GEAP20049184A patent/GEP20125454B/en unknown
- 2004-07-26 CA CA2530005A patent/CA2530005C/en not_active Expired - Fee Related
- 2004-07-26 CN CN2004800215633A patent/CN1829482B/zh not_active Expired - Fee Related
- 2004-07-26 PT PT04779186T patent/PT1646328E/pt unknown
- 2004-07-26 KR KR1020067001688A patent/KR100829492B1/ko not_active IP Right Cessation
- 2004-07-26 NZ NZ545505A patent/NZ545505A/en unknown
- 2004-07-26 UA UAA200602136A patent/UA81056C2/uk unknown
- 2004-07-26 EA EA200600200A patent/EA009921B1/ru not_active IP Right Cessation
- 2004-07-26 AT AT04779186T patent/ATE375149T1/de active
-
2005
- 2005-12-12 ZA ZA200510069A patent/ZA200510069B/en unknown
- 2005-12-19 IS IS8187A patent/IS2630B/is unknown
-
2006
- 2006-01-24 IL IL173346A patent/IL173346A/en not_active IP Right Cessation
- 2006-02-23 MA MA28830A patent/MA28004A1/fr unknown
- 2006-02-24 NO NO20060913A patent/NO333189B1/no not_active IP Right Cessation
-
2007
- 2007-10-12 HR HR20070476T patent/HRP20070476T3/xx unknown
-
2008
- 2008-01-08 CY CY20081100020T patent/CY1107262T1/el unknown
-
2011
- 2011-08-18 JP JP2011179129A patent/JP2011252020A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107262T1 (el) | Θεραπεια της εξαρτησης στερησης | |
| AU2003268144A8 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
| DK1476141T3 (da) | Manipulationssikrede anordninger til transdermal opioidadministration | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| ATE510542T1 (de) | Noribogain zur behandlung von schmerzen und drogenabhängigkeit | |
| ATE405272T1 (de) | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin | |
| JP2002523370A5 (el) | ||
| DK1572167T3 (da) | Transdermal buprenophindoseringsbehandlingsplan for analgesi | |
| HRP20080146T3 (en) | Preoperative treatment of post operative pain | |
| BR0307022A (pt) | Método de tratamento de um paciente que precisa de analgesia | |
| Naber et al. | Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients | |
| DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon |